Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation - Takeaways - MDSpire

Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation

  • By

  • Hanpeng Luo

  • Bing Liu

  • Yaqin Li

  • Peng Cui

  • Tao Zhou

  • Cai Ye

  • Can Wu

  • Junchang Wu

  • Yu Wang

  • Wei V. Zheng

  • May 13, 2026

Share

  • 1

    Mesenchymal stem cells (MSCs) mitigate Concanavalin A-induced acute hepatitis by modulating the hepatic immune microenvironment.

  • 2

    MSC treatment reduces the frequency of myeloid-derived suppressor cells, regulatory T cells, and NK cells while enhancing monocyte-derived macrophages.

  • 3

    Single-cell RNA sequencing revealed that MSCs selectively remodel monocyte-derived macrophage states rather than suppressing all macrophage subsets.

  • 4

    Complement-related signaling was identified as a key communication module in MSC-mediated immune modulation during liver injury resolution.

  • 5

    The study highlights the MSC–macrophage–complement axis as a vital pathway for immunomodulation and tissue repair in acute liver damage.

Original Source(s)

Mesenchymal stem cell alleviate concanavalin A-induced hepatitis via immune reprogramming and complement regulation

  • by Hanpeng Luo, Bing Liu, Yaqin Li, Peng Cui, Tao Zhou, Cai Ye, Can Wu, Junchang Wu, Yu Wang, Wei V. Zheng

  • May 13, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Emergence of Severe and Prolonged Hepatobiliary Disorders Following COVID-19 Infection: A Systematic Analysis

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor